Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

40.49USD
6 Dec 2016
Change (% chg)

$-0.43 (-1.04%)
Prev Close
$40.91
Open
$40.25
Day's High
$40.63
Day's Low
$40.11
Volume
636,680
Avg. Vol
2,339,230
52-wk High
$44.50
52-wk Low
$36.81

Latest Key Developments (Source: Significant Developments)

Sanofi starts phase 3 trial of pompe disease treatment
Friday, 4 Nov 2016 08:00am EDT 

Sanofi Sa : Sanofi genzyme begins pivotal phase 3 trial of neogaa investigational second-generation therapy for pompe disease .Sanofi genzyme begins pivotal phase 3 trial of neogaa investigational second-generation therapy for pompe disease.  Full Article

Regeneron and Sanofi receive complete response letter from FDA for Sarilumab
Friday, 28 Oct 2016 02:35pm EDT 

Sanofi Sa : Regeneron and sanofi receive complete response letter from fda for sarilumab, an investigational treatment for rheumatoid arthritis . Sanofi says sanofi and regeneron remain committed to development of sarilumab and providing therapy to ra patients in u.s. As quickly as possible . Sanofi -if approved by fda, sarilumab would be commercialized by regeneron and sanofi genzyme, specialty care global business unit of sanofi .Sanofi - crl refers to certain deficiencies identified during gmp inspection of facility in france where sarilumab is filled and finished.  Full Article

Myriad RBM announces agreement with Sanofi
Tuesday, 25 Oct 2016 07:05am EDT 

Myriad Genetics Inc : Announces an agreement with Sanofi to measure predictive cardiovascular biomarkers in patients with diabetes . Financial terms of deal were not disclosed .Under agreement, Sanofi will provide approximately 5,300 serum samples from elixa trial.  Full Article

Sanofi reports open market purchase of 450,000 shares of Myokardia
Wednesday, 5 Oct 2016 09:00am EDT 

Sanofi SA : Sanofi reports open market purchase of 450,000 shares Of Myokardia Inc for $15/Share on Oct 3, 2016 .Sanofi's open market purchase of 450,000 shares of myokardia inc made on Oct 3 represents an indirect ownership in Myokardia.  Full Article

Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development
Wednesday, 28 Sep 2016 08:00am EDT 

Immune Design Corp : Application of co's glaas discovery platform in Sanofi's phase 1 clinical trial evaluating a candidate for treatment of peanut allergy . Trial follows exclusive license agreement with co to discover, develop, commercialize products to treat a peanut allergy using GLAAS .Has received undisclosed milestone payment for start of trial, is eligible to receive future development,commercialization milestones.  Full Article

Sanofi says BARDA grants $43.2 million to Sanofi Pasteur for Zika
Monday, 26 Sep 2016 11:05am EDT 

Sanofi : BARDA grants $43.2 million usd to Sanofi Pasteur for Zika . Beyond funding provided by BARDA for two phase i/ii clinical trials, there is an option for continuing support through phase iii . BARDA and U.S. Department of health and human services has agreed to a proposal to fund manufacture of Zika vaccine for phase ii development ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

U.S. Department of health and human services says BARDA awards funding to Sanofi Pasteur for Zika vaccine
Monday, 26 Sep 2016 10:36am EDT 

U.S. department of health and human services: U.S. Department Of Health And Human Services says contract includes an option for up to an additional $130.45 million to fund phase 3 clinical trials . U.S. Department Of Health And Human Services says BARDA awards funding to speed development of Zika vaccine ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Sanofi and Regeneron accepted for priority review by U.S. FDA
Monday, 26 Sep 2016 01:00am EDT 

:Sanofi and Regeneron [REGN.O] announce dupilumab biologics license application accepted for priority review by U.S. FDA.  Full Article

Zealand Pharma announces new timelines for U.S. FDA decision on iglarlixi
Friday, 19 Aug 2016 06:28pm EDT 

Zealand Pharma A/S : Zealand announces new timelines for a U.S. FDA decision on iglarlixi, the fixed-ratio combination of lixisenatide (adlyxintm) and lantus(r), for the treatment of type 2 diabetes . Financial guidance for 2016 remains unchanged . A U.S. regulatory decision on iglarlixi is now expected before end of November 2016 .FDA requested updated information on pen delivery device for iglarlixi as part of new drug application, which was submitted by Sanofi.  Full Article

Sanofi, Pfizer, Gilead & Celgene interested in Medivation - CNBC citing sources
Friday, 29 Jul 2016 09:40am EDT 

: Sanofi, Pfizer, Gilead & Celgene interested in Medivation as company asks for indications of interest by mid-August - CNBC citing sources Further company coverage: [MDVN.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Photo

Sanofi exploring bid for Actelion amid J&J talks: Bloomberg

French drugmaker Sanofi is considering a bid for Swiss biotech company Actelion , rivaling an offer made by U.S. healthcare company Johnson & Johnson , Bloomberg reported.